Healthcare
VYNE Therapeutics Inc.(VYNE)
Live Price
Offline$0.649
-2.41% today
1Y Change
-28.99%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +13.8%
- EPS Growth
- +34.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VYNE Therapeutics Inc. (VYNE) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.65 and down 29.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +13.8%, EPS growth of +34.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.8%, EPS +34.0%, free cash flow +2.8% with operating margin -5219.1% and ROIC -107.1%. Valuation already assumes a fairly strong business story at price/sales 19.2. Stock Foundry combines VYNE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.8% vs +7.6% peer median
Operating Margin
Below sector median
-5219.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +13.8% and EPS at +34.0%, with operating margin around -5219.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -1.9% | -0.6% | -2.7% |
2026 Mar 12, 2026 | -40.0% | +0.7% | +6.5% | +3.9% |
2025 Nov 6, 2025 | +10.5% | -0.3% | +4.5% | +4.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VYNE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VYNE Max Drawdown
-83.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VYNE and SPY.
Company Overview
VYNE Therapeutics Inc.
NASDAQ Global Select
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
- Leadership
- David T. Domzalski
- IPO Date
- Jan 25, 2018
- Employees
- 13
- Street Address
- 520 U.S. Highway 22
- Mailing
- Bridgewater, NJ, 08807
- Region
- Bridgewater, NJ, US
- Reporting Currency
- USD
- Investor Line
- 800 775 7936
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.4
- Price/Sales
- 19.2
- Price/Book
- 1.0
Growth
- Revenue
- +13.8%
- EPS
- +34.0%
- Free Cash Flow
- +2.8%
Profitability
- Gross Margin
- 99.1%
- Operating Margin
- -5219.1%
- Net Margin
- -4646.1%
- ROE
- -74.1%
- ROIC
- -107.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 12.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.